Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Triple Negative Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × tesetaxel × Clear all
NCT03326674 2021-07-30

CONTESSA

Odonate Therapeutics, Inc.

Phase 3 Terminated
685 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03858972 2021-07-30

CONTESSA 2

Odonate Therapeutics, Inc.

Phase 2 Terminated
152 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Odonate Therapeutics, Inc.

Phase 2 Terminated
294 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡